OCUGEN, INC. Deferred Tax Assets, Operating Loss Carryforwards
OCUGEN, INC. (OCGN) had Deferred Tax Assets, Operating Loss Carryforwards of $89.86 million as of 2025-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-03-04
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $89.86M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $67.82M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $58.32M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $48.81M; Deferred Tax Assets, Operating Loss Carryforwards as first filed $51.88M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards | Deferred Tax Assets, Operating Loss Carryforwards as first filed |
|---|---|---|
| 2025-12-31 | $89.86M 10-K · filed 2026-03-04 | |
| 2024-12-31 | $67.82M 10-K · filed 2026-03-04 | |
| 2023-12-31 | $58.32M 10-K · filed 2025-03-05 | |
| 2022-12-31 | $48.81M 10-K · filed 2024-04-16 | $51.88M 10-K · filed 2023-02-28 |
| 2021-12-31 | $52.04M 10-K · filed 2023-02-28 | |
| 2020-12-31 | $35.71M 10-K · filed 2022-02-28 | $35.71M 10-K · filed 2021-03-19 |
| 2019-12-31 | $31.58M 10-K · filed 2021-03-19 | |
| 2018-12-31 | $6.86M 10-K · filed 2020-03-27 | $24.94M 10-K · filed 2019-03-22 |
| 2017-12-31 | $18.54M 10-K · filed 2019-03-22 | |
| 2016-12-31 | $16.15M 10-K · filed 2018-03-15 | |
| 2015-12-31 | $28.20M 10-K · filed 2017-03-16 | |
| 2014-12-31 | $18.93M 10-K · filed 2016-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |